Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | CSK | P41240 | 3/20 | 0.43 |
| ▸ | TEK | Q02763 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485435 | 0.92 | KDR (0.46) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485493 | 0.90 | EGFR (0.42) | SRCKDREGFRAURKBAURKA | |
| SCHEMBL13485434 | 0.87 | SRC (0.44) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485512 | 0.85 | EGFR (0.39) | SRCKDREGFRFYNAURKB | |
| SCHEMBL13485492 | 0.84 | EGFR (0.41) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485511 | 0.79 | EGFR (0.38) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485489 | 0.79 | EGFR (0.41) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485466 | 0.77 | SRC (0.47) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL13485446 | 0.77 | KDR (0.50) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL6583527 | 0.72 | KDR (0.74) | SRCKDRCSKTEKEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | NR4A3, NR4A1, NR5A2 | SRC 1853/4885KDR 1987/4885CSK 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.